Personal information

No personal information available

Activities

Works (6)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Pharmaceuticals
2024-08-05 | Journal article
Contributors: Wenting Zhang; Ziqi Xu; Yamin Shu; Sainan Shu; Qilin Zhang
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

CNS Neuroscience & Therapeutics
2023-09 | Journal article
Contributors: Yamin Shu; Yiling Ding; Lulu Liu; Qilin Zhang
Source: check_circle
Crossref

Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma

International Immunopharmacology
2023-09 | Journal article
Contributors: Yamin Shu; Ying Tang; Yufeng Ding; Qilin Zhang
Source: check_circle
Crossref

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

Drug Safety
2023-09 | Journal article
Contributors: Yamin Shu; Lei Wang; Yiling Ding; Qilin Zhang
Source: check_circle
Crossref

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database

Cancer Medicine
2023-02 | Journal article
Contributors: Yamin Shu; Yufeng Ding; Xucheng He; Yanxin Liu; Pan Wu; Qilin Zhang
Source: check_circle
Crossref

Association of Myocardial Enzyme Abnormality with Clinical Outcomes of Patients with COVID-19: A Retrospective Study

Disease Markers
2021-10-22 | Journal article
Contributors: Qilin Zhang; Ziming Zheng; Yu Zhang; Michael Hawkes
Source: check_circle
Crossref